

Driving T1D Cures Forward, Faster

Through our commitment and focus, JDRF has played a role in nearly every major type 1 diabetes (T1D) advance—every drug, device, cell therapy. People with T1D are doing better today, thanks to significant investments by JDRF to improve the lives of millions affected by the disease. There’s never been a more exciting time for T1D research. Cures are a matter of when, not if. JDRF is moving us forward toward that day, faster.

FY22 Mission Progress

Curing T1D is JDRF’s ultimate goal. Until we have cures, we help people with T1D live healthier lives. And in the past year, we have seen incredible progress.



Four FDA-approved artificial pancreas (AP) systems, including the first tubeless AP system; other improved technologies such as the first FDA-approved algorithm for interoperability; and advanced insulins and drugs that work alongside insulin are helping to reduce dangerous highs and lows.



Cell Therapies are in human clinical trials and so far, are yielding outstanding results. One trial participant has been able to stop taking insulin entirely.



Tzield™ (teplizumab-mzwv), a drug shown to delay onset of T1D for up to 3 years, is now the first FDA-approved disease-modifying therapy for T1D.




We have a diversified, **global research strategy** involving different kinds of cures and improving-lives therapies—all with multiple projects underway.

Leverage Leads the Way

A global leader in the pursuit of insulin therapy independence for people living with diabetes, JDRF accelerates the path to cures by raising funds and allocating them to T1D research and therapy development, and by leveraging our expertise and leadership to bring in additional funding and supporters. This leverage is a key part of JDRF’s strategy to accelerate cures and life-improving therapies. It has empowered us to grow global support of and investment in T1D research.

Fiscal Year 2022 (FY22), we saw:



JDRF invested \$97M in research in FY22, and through our influence within the public and private sectors, we helped raise another \$376M

A total of \$473 million—through funding from other organizations, corporations, and governments, in addition to JDRF—for T1D research and therapy development


Of that \$473 million, **JDRF T1D Fund**—our venture philanthropy fund established to address the lack of private investment in T1D therapy research and development—catalyzed **\$158.2M*** in private investment in companies developing T1D treatments

*This \$158.2M accounts for the majority of the \$171M of the "Industry Partnerships and Investments" section in the triangle graphic left

More than \$1 Billion to Cures and Improving Lives

During the past 5 fiscal years, through JDRF's research grants and JDRF T1D Fund investments (those that we have made, as well as private, alongside investments), **more than \$1 billion** has been directed to cure T1D and improve lives—with most of it (approximately 80%) focused on cures.

JDRF Grants and T1D Fund Investments: FY18 through FY22




FY22 JDRF Revenue

JDRF has four main revenue streams: Events (Walk, Ride, Gala, etc.); Contributions (gifts, etc.); Investment Gains/Losses (JDRF T1D Fund and Foundation investments), and International Affiliates/Other (funding raised by our five International Affiliates, other sources).

For FY22, we saw increases in our Events, Contributions, and International Affiliates/Other revenue streams. Given the downturn of the financial markets, we also saw a loss in our Investment Gains/Losses revenue stream.

In addition to our T1D Fund portfolio, JDRF maintains an investment portfolio to provide an appropriate level of liquidity and operating reserves. This helps ensure that JDRF can continue to advance mission, regardless of the economy.




Why Did We See a Loss in Investment Gains/Losses?

Calendar year 2022 was the worst year for financial markets since the financial crisis of 2008. As such, in FY22 JDRF saw a loss of \$32 million in our Investment Gains/Losses revenue stream. Peer nonprofit organizations across the country have experienced similar losses. JDRF's financial health remains strong, and the challenging economic environment did not impact our research grant funding. So too, our T1D Fund's portfolio remains strong as we look forward beyond 2022.

FY22 Mission Spend

As we returned to in-person fundraising events, we saw more revenue we could deploy to mission.

In FY22, JDRF spent 50% more on advancing our mission than we did in FY21. This includes a 69% spending increase over FY21 for research funding and investments (grants, support, advocacy, and new T1D Fund investment), and a 16% spending increase over FY21 in public education/community engagement.



JDRF T1D Fund

In 2016, a group of JDRF volunteers identified the need to attract more private investment for the development of T1D cure therapies. Their vision resulted in the creation of the T1D Fund, an impact investment fund that has used a venture philanthropic approach to catalyze over \$700 million of private investment in our mission and transformed the fight to cure T1D. The Fund's unique approach to philanthropy relies on offering the global network and knowledge of JDRF and the Helmsley Charitable Trust as a resource for investors. This unparalleled source of expertise, delivered through a professional venture fund, has created a bridge between research and commercial development and has activated the biotech industry to translate research into T1D cure therapies. The FDA approval of Tzield is an example of a program that benefited from early investment and support by the Fund.

As of June 2022, the Fund has invested ~\$81 million in 31 companies and has attracted more than \$634 million of private capital alongside it to be used in T1D programs. In addition, the Fund's investment strategy has resulted in more than \$54 million of returns recycled back for future investment. Funded by over \$100 million of gifts from just over 100 donors and support from JDRF, in six years the T1D Fund has become one of the largest disease-focused venture philanthropy funds in the world and the only one focused on T1D.